Xuanzhu Biopharm, an innovative drug research and development company, recently has completed its Series A round of financing, raising 800 million yuan from SDIC.
CASIVision recently announced that it had completed the Series A+ round of financing worth 90 million yuan in the first half of the year. This round of financing was jointly led by Zhongke Haichuang and SDIC.
On July 10, underwater intelligent equipment enterprise Deepinfar Ocean Technology announced the closing of its Series B+ financing round, raising 120 million yuan.
The round was completed by new and existing investors, including SDIC, Minsheng Securities Investment, TEDA VC, and VStar Capital.